CCL21 Cancer Immunotherapy

被引：44

作者：

Lin, Yuan ^{[1
,2
,3
,4
,5
]}

Sharma, Sherven ^{[2
,4
,5
,6
]}

John, Maie St. ^{[1
,2
,3
,4
]}

机构：

[1] UCLA, David Geffen Sch Med, Dept Head & Neck Surg, 10833 Conte Ave, Los Angeles, CA 90095 USA

[2] UCLA, David Geffen Sch Med, Jonsson Comprehens Canc Ctr, 10833 Conte Ave, Los Angeles, CA 90095 USA

[3] UCLA, David Geffen Sch Med, UCLA Head & Neck Canc Program, 10833 Conte Ave, Los Angeles, CA 90095 USA

[4] UCLA, David Geffen Sch Med, Clin & Translat Sci Inst, 10833 Conte Ave, Los Angeles, CA 90095 USA

[5] UCLA, David Geffen Sch Med, Dept Med, Div Pulm & Crit Care Med, 37-131 CHS,10833 Conte Ave, Los Angeles, CA 90095 USA

[6] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA

来源：

CANCERS | 2014年 / 6卷 / 02期

基金：

美国国家卫生研究院;

关键词：

CCL21; cancer immunotherapy; dendritic cell; polymer; T cell;

D O I：

10.3390/cancers6021098

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Cancer, a major health problem, affects 12 million people worldwide every year. With surgery and chemo-radiation the long term survival rate for the majority of cancer patients is dismal. Thus novel treatments are urgently needed. Immunotherapy, the harnessing of the immune system to destroy cancer cells is an attractive option with potential for long term anti-tumor benefit. Cytokines are biological response modifiers that stimulate anti-tumor immune responses. In this review, we discuss the anti-tumor efficacy of the chemotactic cytokine CCL21 and its pre-clinical and clinical application in cancer.

引用

页码：1098 / 1110

页数：13

共 59 条

[1] Enhancement of antitumor immunity against B16 melanoma tumor using genetically modified dendritic cells to produce cytokines [J].